Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?
- PMID: 38823378
- DOI: 10.1055/s-0044-1787299
Are the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?
Conflict of interest statement
J.K.S. received consulting fees from Pfizer, Sanofi. G.D.B. received grant funding from Boston Scientific; Consulting: Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, Boston Scientific; He also is a member of Board of Directors for Anticoagulation Forum.
Comment on
-
Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC.Thromb Haemost. 2024 Aug;124(8):778-790. doi: 10.1055/a-2168-9378. Epub 2023 Sep 6. Thromb Haemost. 2024. PMID: 37673103 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical